Literature DB >> 24002218

Characterization of levofloxacin non-susceptible clinical Streptococcus pyogenes isolated in the central part of Italy.

D Petrelli1, M C Di Luca, M Prenna, P Bernaschi, A Repetto, L A Vitali.   

Abstract

We investigated the prevalence, genetics, and clonality of fluoroquinolone non-susceptible isolates of Streptococcus pyogenes in the central part of Italy. S. pyogenes strains (n = 197) were isolated during 2012 from patients with tonsillopharyngitis, skin, wound or invasive infections and screened for fluoroquinolone non-susceptibility (resistance to norfloxacin and levofloxacin minimum inhibitory concentration (MIC) = 2 mg/L) following EUCAST guidelines. First-step topoisomerase parC and gyrA substitutions were investigated using sequencing analysis. Clonality was determined by pulsed field gel electrophoresis (PFGE; SmaI digestion) and by emm typing. The fluoroquinolone non-susceptible phenotype was identified in 18 isolates (9.1 %) and correlated with mutations in parC, but not in gyrA, the most frequent leading to substitution of the serine at position 79 with an alanine. Most of the fluoroquinolone non-susceptible isolates belonged to the emm-type 6, even if other emm-types were also represented (emm75, emm89, and emm2). A significant level of association was measured between PFGE and both emm type and substitutions in parC. The prevalence of fluoroquinolone non-susceptible Streptococcus pyogenes isolates in Italy is of concern and, although the well-known emm type 6 is dominant, other types are appearing and spreading.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24002218     DOI: 10.1007/s10096-013-1950-5

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  17 in total

1.  Characterization of clinical Streptococcus pneumoniae strains from Germany with decreased susceptibility to fluoroquinolones.

Authors:  Ralf René Reinert; Adnan Al-Lahham; Rudolf Lütticken; Mechthild Boos; Franz-Josef Schmitz
Journal:  J Antimicrob Chemother       Date:  2002-06       Impact factor: 5.790

2.  Streptococcus pyogenes pharyngeal isolates with reduced susceptibility to ciprofloxacin in Spain: mechanisms of resistance and clonal diversity.

Authors:  Sebastián Albertí; Guadalupe Cortés; Cesar García-Rey; Carmen Rubio; Fernando Baquero; José Angel García-Rodríguez; Emilio Bouza; Lorenzo Aguilar
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

3.  Emergence of ciprofloxacin-nonsusceptible Streptococcus pyogenes isolates from healthy children and pediatric patients in Portugal.

Authors:  Renato Pires; Carmen Ardanuy; Dora Rolo; Ana Morais; António Brito-Avô; José Gonçalo-Marques; Josefina Liñares; Ilda Santos-Sanches
Journal:  Antimicrob Agents Chemother       Date:  2010-03-29       Impact factor: 5.191

4.  The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools.

Authors:  J D Thompson; T J Gibson; F Plewniak; F Jeanmougin; D G Higgins
Journal:  Nucleic Acids Res       Date:  1997-12-15       Impact factor: 16.971

5.  Increase in fluoroquinolone non-susceptibility among clinical Streptococcus pyogenes in Belgium during 2007-10.

Authors:  Liesbet Van Heirstraeten; Gert Leten; Christine Lammens; Herman Goossens; Surbhi Malhotra-Kumar
Journal:  J Antimicrob Chemother       Date:  2012-07-19       Impact factor: 5.790

6.  Erythromycin resistance in italian isolates of Streptococcus pyogenes and correlations with pulsed-field gel electrophoresis analysis.

Authors:  Claudia Zampaloni; Luca A Vitali; Manuela Prenna; Maria A Toscano; Gianna Tempera; Sandro Ripa
Journal:  Microb Drug Resist       Date:  2002       Impact factor: 3.431

7.  Prevalence and characterization of invasive isolates of Streptococcus pyogenes with reduced susceptibility to fluoroquinolones.

Authors:  Jeff Powis; Allison McGeer; Carla Duncan; Ryan Goren; Joyce C S de Azavedo; Darrin J Bast; Sylvia Pong-Porter; Tony Mazzulli; Karen Green; Barbara Willey; Donald E Low
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

8.  Characterisation of fluoroquinolone-resistant clinical isolates of Streptococcus pyogenes in Barcelona, Spain.

Authors:  A Rivera; M Rebollo; F Sánchez; F Navarro; E Miró; B Mirelis; P Coll
Journal:  Clin Microbiol Infect       Date:  2005-09       Impact factor: 8.067

9.  Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.

Authors:  Surbhi Malhotra-Kumar; Liesbet Van Heirstraeten; Christine Lammens; Sabine Chapelle; Herman Goossens
Journal:  J Antimicrob Chemother       Date:  2009-03-11       Impact factor: 5.790

10.  Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain.

Authors:  Milagrosa Montes; Esther Tamayo; Beatriz Orden; Julián Larruskain; Emilio Perez-Trallero
Journal:  Antimicrob Agents Chemother       Date:  2009-10-05       Impact factor: 5.191

View more
  2 in total

1.  Changes in Macrolide Resistance Among Group A Streptococci in Serbia and Clonal Evolution of Resistant Isolates.

Authors:  Ina Gajic; Vera Mijac; Lazar Ranin; Edita Grego; Dusan Kekic; Boris Jegorovic; Aleksandra Smitran; Suncica Popovic; Natasa Opavski
Journal:  Microb Drug Resist       Date:  2018-03-20       Impact factor: 3.431

2.  Identification and Characterization of Fluoroquinolone Non-susceptible Streptococcus pyogenes Clones Harboring Tetracycline and Macrolide Resistance in Shanghai, China.

Authors:  Yinfang Shen; Jiehao Cai; Mark R Davies; Chi Zhang; Kun Gao; Dan Qiao; Haoqin Jiang; Weilei Yao; Yuefang Li; Mei Zeng; Mingliang Chen
Journal:  Front Microbiol       Date:  2018-03-23       Impact factor: 5.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.